Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVDL vs PTGX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 44.6 HOLD), While PTGX Leads 5–1 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: AVDL 1 – 5 PTGX Matrix Metrics: AVDL 5 – 5 PTGX

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Protagonist Therapeutics, Inc (PTGX) on higher Unified Composite conviction (62.9/100 BUY vs. 44.6/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while PTGX wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus PTGX at $121.40 (36.9x Forward P/E, 58.6% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. PTGX 44.6/100 HOLD) and 0.14β · 2% Vol risk profile, whereas PTGX leads top-line expansion (+5723.6% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile PTGX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVDL vs PTGX
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50
PTGX NASDAQ
Protagonist Therapeutics, Inc
Pharmaceutical Preparations
$121.40
-2.11% 1D
Market Cap $8.1B
TTM Revenue $552M
Forward P/E 36.9x
Beta / 30D Vol 0.97β · 36% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 26.0 Fund 49.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 31
RSI-14: 31.4 · SMA20: $134.87 · SMA50: $138.14

6-Pillar Scorecard Institutional Category Breakdown (AVDL 1 – 5 PTGX)

Columns: Metric · AVDL · PTGX
1. Valuation Multiples AVDL
Forward P/E 28.8x 36.9x
Trailing P/E 16.8x 26.2x
PEG Ratio 0.07x N/M
EV / Revenue 8.5x 13.8x
2. Growth & Scale PTGX
Revenue Growth (YoY) +54.9% +5723.6%
Earnings Growth (YoY) +0.0% +351.3%
TTM Revenue (USD) $249M $552M
Market Cap $2.1B $8.1B
3. Profitability & Quality PTGX
Gross Margin 94.9% 99.8%
Operating Margin 2.5% 58.6%
Net Profit Margin -0.1% 62.0%
Return on Equity (ROE) -0.3% 39.6%
4. Balance Sheet & Cash Flow PTGX
Cash Generation (TTM) $2.7M EBITDA $109M
Cash Flow Margin 1.1% EBITDA Mgn 19.8%
Net Cash / Leverage $1.01 Book/Sh · -0.3% ROE $490M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PTGX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 2.4% (<1st %ile) 103.2% (16th %ile)
Put/Call OI Skew N/A 2.89x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat PTGX
OpEx & R&D Intensity N/A 41.2% of Rev ($227M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVDL (5) vs PTGX (5)
Institutional Metric AVDL PTGX Criterion Row Edge
Market Capitalization
Scale
$2.1B $8.1B Larger Scale PTGX
Trailing P/E Ratio
Valuation
16.8x 26.2x Lower Multiple AVDL
Forward P/E Ratio
Valuation
28.8x 36.9x Lower Multiple AVDL
Revenue Growth (YoY)
Growth
+54.9% +5723.6% Higher Growth PTGX
Operating Margin (TTM)
Profitability
2.5% 58.6% Higher Margin PTGX
Net Profit Margin
Profitability
-0.1% 62.0% Higher Margin PTGX
Return on Equity (ROE)
Capital Efficiency
-0.3% 39.6% Higher ROE PTGX
52-Week Range Position
Momentum
89% ($6–$24) 53% ($77–$161) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.14β · 2% Vol 0.97β · 36% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 44.6 / 100 (HOLD) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$249M $552M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
94.9% 99.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.07x PEG · 8.5x EV/Rev N/M PEG · 13.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) $109M ($490M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTGX +3.39 pp
AVDL: +0.65% · PTGX: +4.04%
3M Horizon PTGX +4.39 pp
AVDL: -6.32% · PTGX: -1.93%
6M Horizon PTGX +4.39 pp
AVDL: -6.32% · PTGX: -1.93%
1Y Horizon PTGX +4.39 pp
AVDL: -6.32% · PTGX: -1.93%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs PTGX. Trailing 12-month operating profitability (AVDL 2.5% vs PTGX 58.6%) and valuation multiples (AVDL 28.8x vs PTGX 36.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x
PTGX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$552M
Gross Margin99.8%
Op. Margin58.6%
ROE / Fwd P/E39.6% · 36.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTGX CONSOLIDATION
68d in phase · OBV DISTRIBUTION
Current IV 103.2%
IV Percentile 16th %ile
Put/Call OI Skew 2.89x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PTGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PTGX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $8.1B market capitalization and 58.6% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($227M)
90D Engineering Disclosures 0 Published

Investor FAQ AVDL vs PTGX Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Protagonist Therapeutics, Inc (PTGX) on higher Unified Composite conviction (62.9/100 BUY vs. 44.6/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples), while PTGX wins 5–1 across the 6-pillar growth and valuation breakdown. AVDL trades at $21.64 (28.8x Forward P/E, 2.5% operating margin) versus PTGX at $121.40 (36.9x Forward P/E, 58.6% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. PTGX 44.6/100 HOLD) and 0.14β · 2% Vol risk profile, whereas PTGX leads top-line expansion (+5723.6% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3); meanwhile PTGX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTGX leads the Growth & Scale pillar: AVDL posts +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin), compared with PTGX at +5723.6% YoY revenue growth and +351.3% YoY earnings growth on $552M TTM revenue (99.8% gross margin, 58.6% operating margin). On trailing 12-month operating scale, AVDL generates $249M in USD-normalized revenue versus $552M for PTGX. In operating R&D and SG&A reinvestment, AVDL deploys N/A (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($227M) (0 disclosures) for PTGX.

AVDL screens cheaper on headline valuation multiples. AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin), whereas PTGX trades at 36.9x Forward P/E, 26.2x Trailing P/E, N/M PEG, and 13.8x EV/Revenue (19.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVDL (-0.3% ROE) versus PTGX (39.6% ROE) capital efficiency.

In options market volatility and institutional positioning, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk). By comparison, PTGX carries 103.2% implied volatility (16th %ile, Compressed (<25th %ile)), a 2.89x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.97β · 36% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.